Drug intelligence / Profile preview

orlistat + resveratrol

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules
Administration: Oral

Overview

Orlistat + resveratrol is a combination drug therapy for weight management in individuals with obesity or overweight. Orlistat works by decreasing fat absorption from food, while resveratrol is a polyphenol that may provide additional metabolic benefits. Clinical trials have shown this combination to be more effective for weight loss than either component alone or placebo, with additional benefits for liver health in patients with hepatic steatosis.

Brand names: Zytrim-R
Other names: O-R combination

Targets

LIPF (Gastric lipase)PNLIP (Pancreatic triacylglycerol lipase)

Beyond the preview

Go deeper on orlistat + resveratrol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on orlistat + resveratrol.

Explore the full profile